155 related articles for article (PubMed ID: 9847434)
1. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.
Nathan RA; Bernstein JA; Bielory L; Bonuccelli CM; Calhoun WJ; Galant SP; Hanby LA; Kemp JP; Kylstra JW; Nayak AS; O'Connor JP; Schwartz HJ; Southern DL; Spector SL; Williams PV
J Allergy Clin Immunol; 1998 Dec; 102(6 Pt 1):935-42. PubMed ID: 9847434
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
Tashkin DP; Nathan RA; Howland WC; Minkwitz MC; Simonson SG; Bonuccelli CM
J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):246-54. PubMed ID: 9949315
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.
Kemp JP; Minkwitz MC; Bonuccelli CM; Warren MS
Chest; 1999 Feb; 115(2):336-42. PubMed ID: 10027429
[TBL] [Abstract][Full Text] [Related]
4. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.
Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM
Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM
Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920
[TBL] [Abstract][Full Text] [Related]
6. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness.
Nathan RA; Minkwitz MC; Bonuccelli CM
Ann Allergy Asthma Immunol; 1999 May; 82(5):497-503. PubMed ID: 10353583
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA
J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S
Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K
J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial.
Grossman J; Smith LJ; Wilson AM; Thyrum PT
Ann Allergy Asthma Immunol; 1999 Apr; 82(4):361-9. PubMed ID: 10227334
[TBL] [Abstract][Full Text] [Related]
12. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT).
Korenblat PE; Kemp JP; Scherger JE; Minkwitz MC; Mezzanotte W
Ann Allergy Asthma Immunol; 2000 Feb; 84(2):217-25. PubMed ID: 10719780
[TBL] [Abstract][Full Text] [Related]
13. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.
Kemp JP; Cook DA; Incaudo GA; Corren J; Kalberg C; Emmett A; Cox FM; Rickard K
J Allergy Clin Immunol; 1998 Feb; 101(2 Pt 1):188-95. PubMed ID: 9500751
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data.
Centanni S; Santus P; Casanova F; Di Marco F; Brazzola G; Canonica GW
Drugs Exp Clin Res; 2000; 26(4):133-8. PubMed ID: 11109513
[TBL] [Abstract][Full Text] [Related]
15. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
Virchow JC; Prasse A; Naya I; Summerton L; Harris A
Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
[TBL] [Abstract][Full Text] [Related]
16. [Influence of zafirlukast on pulmonary functions and quality of life in patients with asthma].
Xiang XD; Zhou R; Chen Y
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):251-3. PubMed ID: 12536697
[TBL] [Abstract][Full Text] [Related]
17. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
Nathan RA; Bleecker ER; Kalberg C;
Am J Med; 2001 Aug; 111(3):195-202. PubMed ID: 11530030
[TBL] [Abstract][Full Text] [Related]
18. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and rebound with zafirlukast in patients with persistent asthma.
Reid DW; Misso NL; Aggarwal S; Thompson PJ; Johns DP; Walters EH
J Negat Results Biomed; 2008 May; 7():3. PubMed ID: 18489783
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Zafirlukast ('Accolate') in the management of patients with mild-to-moderate asthma.
Chukwu C; Okpapi J; Ige MO; Obodo JO
West Afr J Med; 2000; 19(2):111-9. PubMed ID: 11070746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
